| 发明名称 | Methods for Alzheimer's disease treatment and cognitive enhancement | ||
| 摘要 | The present invention relates to compositions and methods to modulate α-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s). | ||
| 申请公布号 | US9539235(B2) | 申请公布日期 | 2017.01.10 |
| 申请号 | US201313851161 | 申请日期 | 2013.03.27 |
| 申请人 | COGNITIVE RESEARCH ENTERPRISES, INC | 发明人 | Etcheberrigaray Rene;Alkon Daniel L. |
| 分类号 | A61K31/335;A61K31/35;A61K31/365;A61K31/00;A61K31/366;A61K9/00 | 主分类号 | A61K31/335 |
| 代理机构 | Finnegan, Henderson, Farabow, Garrett & Dunner LLP | 代理人 | Finnegan, Henderson, Farabow, Garrett & Dunner LLP |
| 主权项 | 1. A method for treating Alzheimer's disease, comprising administering a macrocyclic lactone chosen from bryostatin-2, bryostatin-3, bryostatin-4, bryostatin-5, bryostatin-6, bryostatin-7, bryostatin-8, bryostatin-9, bryostatin-10, bryostatin-11, bryostatin-12, bryostatin-13, bryostatin-14, bryostatin-15, bryostatin-16, bryostatin-17, and bryostatin 18 in a pharmaceutically acceptable carrier to a human patient in an amount effective to treat Alzheimer's Disease. | ||
| 地址 | Morgantown WV US | ||